A study in scleroderma and systemic sclerosis might look into the effectiveness and safety in a specific medical treatment, it might focus on the risk factors in pregnancy for women with scleroderma – or something completely different.
Studying this rare disease help us in working towards achieving the best possible standards of care, and ultimately a cure.
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
University of Nicosia in Cyprus, where medical students are in the medical program of St George’s from the University of London, is conducting a study to analyse the most common and high-risk pregnancy complications experienced by women with rheumatic diseases.
Patients with systemic sclerosis who are planning a pregnancy may be interested in participating in an international observational prospective study on pregnancy in women with systemic sclerosis.
Read latest FASST newsletter on the research.
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
The diagnostic rate of systemic sclerosis demonstrates a strong gender bias.
FESCA, Federation of European Scleroderma Associations aisbl, encourages and undertake surveys, research projects and clinical trials related to the systemic sclerosis disease, and the publication of the results of any such research.
FESCA is always looking for better therapies. This is why we are partners with many different pharma companies. Pay our Scleroderma projects section a visit, and learn more about scleroderma research projects we're involved in.